During this podcast, we will discuss the causes and implications of Adventitious Agent Contamination for pharmaceutical and biopharmaceutical manufacturers. We will discuss ways in which Lancaster Laboratories is helping manufacturers minimize the risk for this contamination to avoid production delays.
Jeri Ann Boose, Ph.D.
Director, Biopharmaceutical Services
Katherine Bergmann, Ph.D.
Manager, Viral Safety and Viral Clearance Services